NASDAQ$ASTH

Astrana Health Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Apollo Medical Holdings reported record revenue and net income growth for 2020, beating annual guidance.

ApolloMed announced its consolidated financial results for the fourth quarter and year ended December 31, 2020, achieving record top and bottom line growth due to the NGACO's performance, acquisitions, decreased utilization, and increased operational efficiencies.

  • ApolloMed achieved record top and bottom line growth in 2020.
  • The company benefited from its NGACO's performance and acquisitions.
  • Decreased utilization and increased operational efficiencies contributed to growth.
  • ApolloMed announced a strategic investment and alliance with CAIPA MSO in New York.

Headline financials

Total Revenue

$39.7M

Previous: $179M-77.8%
EPS (adj)

$0.27

Previous: $0.20+35.0%
Capital Expenditures

$611K

Previous: $235K+159.9%
Free Cash Flow

-$3.21M

Previous: $3.35M-195.8%
Net Income

$0.00

Previous: $6.73M-100.0%
Operating Income

$0.00

Previous: $10.9M-100.0%
Gross Profit

$39.7M

Previous: $26.9M+47.7%
Cash & Equivalents

$0.00

Previous: $103M-100.0%
Total Assets

$0.00

Previous: $729M-100.0%
Stock-Based Comp

$825K

Previous: $541K+52.5%

Revenue & EPS history

Astrana Health · Revenue · Quarterly

$39.7M

Q4 2020-77.8%vs Q4 2019
Beat estimate in 8 of 13 quarters(62%)
ActualEstimate

Forward guidance

ApolloMed provided guidance for total revenue, net income, EBITDA, and Adjusted EBITDA for the year ending December 31, 2021, based on existing business and market conditions.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

+0.7%

Avg return

Earnings day

-2.1%

Avg return

5 days after

+2.1%

Avg return

30 days after

40%

23 / 57 earnings

Positive

+83.3%

Q3 2011

Best reaction

-40.5%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+29.4%+22.5%+20.6%
Q3 2025-23.4%-29.4%-33.8%
Q1 2025-11.1%-20.8%-24.5%
Q4 2024-26.8%+5.0%+16.1%
Q3 2024-21.1%-27.9%-30.4%
Q2 2024-1.4%-1.8%+0.1%
Q1 2024-0.7%+1.5%+8.0%
Q4 2023+2.3%+1.8%-1.9%
Q3 2023+9.3%+2.9%+13.4%
Q2 2023+4.2%+3.5%-17.4%
Q1 2023+5.4%+7.0%-0.8%
Q4 2022+6.9%+5.2%+15.2%
Q3 2022+8.4%+8.9%-14.5%
Q2 2022-4.3%-11.0%-29.3%
Q1 2022-0.5%-5.4%-26.4%
Q4 2021-2.0%-11.0%-7.0%
Q3 2021+14.7%+30.5%+0.8%
Q2 2021-11.8%-10.7%-12.9%
Q1 2021+4.5%+4.7%+10.9%
Q4 2020+9.1%+8.8%+8.3%
Q3 2020-1.2%-1.6%+0.5%
Q2 2020+1.8%+2.4%+7.9%
Q1 2020-10.4%-11.6%+13.1%
Q4 2019-12.9%-24.0%+7.0%
Q3 2019-2.9%-0.9%+25.0%
Q2 2019-5.0%+4.8%+31.1%
Q1 2019-1.2%-4.3%-29.7%
Q4 2018-6.4%-8.3%-6.9%
Q3 2018+26.3%+4.0%-4.6%
Q2 2018-13.7%-23.3%-32.2%
Q4 2017+10.8%-6.3%+2.1%
Q1 2018+10.8%-6.3%+2.1%
Q3 2017+3.9%+3.9%+140.0%
Q2 2017+0.0%+0.0%-10.5%
Q1 2017+0.0%+6.7%+36.7%
Q1 2016+4.0%+4.0%+0.0%
Q3 2016-4.8%
Q2 2016-12.9%
Q1 2015-6.5%
Q3 2015-3.2%
Q2 2015+0.0%
Q2 2014+15.6%
Q4 2013
Q3 2013+1.6%
Q2 2013+13.5%
Q1 2013-13.3%
Q4 2012-2.2%
Q3 2012-9.1%
Q2 2012-40.5%
Q1 2012+0.0%
Q4 2011
Q3 2011+83.3%
Q2 2011+0.5%
Q1 2011-0.5%
Q4 2010-3.9%
Q3 2010+19.0%
Q2 2010+0.0%
Q1 2010-2.1%
Q4 2009+9.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro